Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue

  • STATUS
    Recruiting
  • End date
    Jan 1, 2027
  • participants needed
    500
  • sponsor
    National Cancer Institute (NCI)
Updated on 17 June 2022
cancer
urine test
bladder cancer
bladder tumor
Accepts healthy volunteers

Summary

Background

Urothelial cancer is cancer of the bladder, ureter, and urethra. Researchers want to better understand what changes in a person s cells and genes cause this cancer to form. This may help them find new ways to treat it.

Objective
  • To perform DNA sequencing to help researchers learn the differences between normal tissue and tumor tissue. Also, to learn how molecular changes - including gene changes - might help predict the course of disease and how people respond to therapy.
Eligibility
  • Adults age 18 and older who have or are suspected of having urothelial cancer or an inherited disorder that raises their risk of getting bladder cancer.
Design
  • Participants will be screened with a physical exam. Their medical records and tissue samples will be reviewed.
  • Eligible participants will give tissue blocks of their original tumor. The blocks will be put in a tissue bank.
  • Participants medical records may be reviewed.
  • Participants may have a medical history and physical exam.
  • Participants may have blood and urine tests. They may have imaging scans. They may give urine, blood, and saliva samples. These samples may be used in future research.
  • If participants need surgery for their cancer, researchers will keep some of the tissue (both tumor and normal tissue). The tissue may be used in future research.
  • Participants will go back to the Clinical Center in 6 months. They may give saliva, urine, and blood samples. After 6 months, they will be seen by their local doctor for standard post-surgical visits.
  • Participants will be called every 6 months to give health updates.

Description

Background
  • Urothelial carcinoma, present as lower or upper urinary tract disease, is the most expensive malignancy to treat from diagnosis to death, and no major advances in drug therapy have taken place in the last two decades.
  • Understanding the molecular mechanisms and genomic alterations that cause urothelial carcinoma will provide the foundation for the development of novel targeted therapeutic agents for this disease. Since 1982 investigators in the Urologic Oncology Branch have been studying the genetic basis of urologic cancers. The identification of the genes for cancer of the kidney has led to the approval by the FDA of a number of new agents for patients with advanced disease. Similarly, it is our goal to study the cancer biology (genomic, molecular, and cellular biology) of urothelial carcinoma in order to develop novel treatment strategies.
  • Collection of patient tumor samples allows us to study molecular and biologic pathways and develop novel targeted therapies. Correlation of these samples with clinical outcomes in patients allows us to predict and understand clinical outcomes and possibly develop predictive and/or prognostic biomarkers.
  • Collection of blood, urine and saliva from healthy volunteers will allow us to distinguish normal and inflammatory conditions from malignant diseases. Furthermore, the specimens will provide appropriate controls for comparison.

Objective (Primary):

  • Collect blood, urine, and benign and malignant tissue from patients with known or suspected urothelial cancer for the purpose of elucidating the molecular mechanisms of carcinogenesis in urothelial cancer and ultimately, identifying novel therapeutic targets.
  • Collect blood, urine and saliva from healthy volunteers for the purpose of establishing controls for comparison with urothelial cancer specimens.
    Eligibility
  • Adults with biopsy-proven or suspected urothelial cancer who require diagnostic or therapeutic intervention as part of their diagnosis, standard of care treatment, or followup/surveillance for their neoplasm.
  • Healthy volunteers from whom blood, saliva and urine samples are easily obtainable.
    Design
  • Care of the patient with urothelial carcinoma will be provided as per medically indicated standards and in the process, normal and malignant urothelial cancer tissues may be obtained at the time of clinically indicated diagnostic and/or therapeutic intervention.
  • Blood, urine, and saliva samples for research may be obtained from patients and healthy volunteers at baseline. Additionally, blood and urine may be collected from patients at follow-up intervals.
  • No investigational or experimental therapy will be given as part of this protocol.

Details
Condition Bladder Cancer, Urinary Tract Cancer, Urothelial Cancer, Healthy Volunteers
Clinical Study IdentifierNCT02379429
SponsorNational Cancer Institute (NCI)
Last Modified on17 June 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Adults (greater than or equal to 18 years of age) and able to give informed consent

Exclusion Criteria

Subjects who are pregnant
Diagnosis of cancer requiring treatment other than minor resection of basal cell or squamous cell skin cancers
Heart, lung, kidney disease, or other medical conditions as per Principal Investigator discretion
History of acute or chronic hepatitis B/C or HIV infection. Patients who are HIV positive are excluded from this study because treatment with immunomodulatory agents for immunosuppressed patients would affect sample analysis and skew the data
Healthy volunteers who are family members with germline mutations
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note